<DOC>
	<DOCNO>NCT01353911</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral activity grazoprevir ( MK-5172 ) administer combination peginterferon alfa-2b ( Peg-IFN ) ribavirin ( RBV ) treatment-naïve ( TN ) participants chronic hepatitis C .</brief_summary>
	<brief_title>Grazoprevir ( MK-5172 ) Administered With Peginterferon Ribavirin Treatment-Naïve Participants With Chronic Hepatitis C ( MK-5172-003 )</brief_title>
	<detailed_description>Amendment 4 unblinded treatment interim analysis subsequently enrol TN participant ( Second Cohort ) receive grazoprevir 400 800 mg daily , down-dosed 100 mg daily Treatment Week ( TW ) 3 TW12 remainder 12-week treatment course . Amendment 5 allow treatment-naïve participant chronic hepatitis C compensate cirrhosis enrol receive open-label grazoprevir 100 mg combination Peg-IFN RBV , without correspond control arm .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Has previously document chronic hepatitis C genotype 1 ( CHC GT 1 ) infection Has hepatitis C virus ( HCV ) ribonucleic acid ( RNA value ) ≥10,000 IU/mL Body weight ≥40 kg ( 88 lb ) ≤125 kg ( 275 lb ) Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom decompensated liver disease Had liver biopsy within 3 year screen screen Day 1 histology consistent CHC evidence cirrhosis hepatocellular carcinoma cause chronic liver disease ( participant compensate cirrhosis , liver biopsy demonstrate cirrhosis regardless length time since biopsy ) Female childbearing potential male female sexual partner childbearing potential agrees use two acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation For participant compensate cirrhosis , evidence cirrhosis without evidence hepatocellular carcinoma ( confirm ultrasound within 4 week prior ) Is pregnant , breastfeeding , plan become pregnant donate egg Is human immunodeficiency virus ( HIV ) positive know coinfected hepatitis B virus Has receive prior approve investigational treatment hepatitis C Has evidence hepatocellular carcinoma evaluation hepatocellular carcinoma For participant compensate cirrhosis : alphafetoprotein level ≥100 ng/mL Has evidence active suspected malignancy , history malignancy , within last 5 year Has evidence history chronic hepatitis cause HCV Is diabetic and/or hypertensive clinically significant ocular examination finding : retinopathy , cotton wool spot , optic nerve disorder , retinal hemorrhage , clinically significant abnormality Has know medical condition could interfere participation completion study Preexisting psychiatric condition include limited moderate severe depression , suicidal homicidal ideation attempt , schizophrenia , psychosis , bipolar disorder , post traumatic stress disorder , mania Is currently participate participate study investigational compound device within 30 day sign informed consent Member family member study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>